Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation

This publication has 6 references indexed in Scilit:

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
  The Lancet Oncology, 2010
• ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
  Journal of Thoracic Oncology, 2009
• Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
  Annals of Surgical Oncology, 2009
• Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
  Journal of Clinical Oncology, 2009
• EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
  Clinical Cancer Research, 2008
• Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
  European Respiratory Journal, 2008